SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - FRA:1SXP - DE000A3ENQ51 - Common Stock
21.65 EUR
+0.05 (+0.23%)
1SXP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 19 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
1SXP had a positive operating cash flow in the past year.
1SXP had positive earnings in each of the past 5 years.
1SXP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.61%, 1SXP belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
The Return On Equity of 1SXP (17.01%) is better than 94.74% of its industry peers.
1SXP's Return On Invested Capital of 13.93% is amongst the best of the industry. 1SXP outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is significantly above the industry average of 7.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROIC | 13.93% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a Profit Margin of 15.05%. This is in the better half of the industry: 1SXP outperforms 78.95% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
1SXP's Operating Margin of 19.47% is fine compared to the rest of the industry. 1SXP outperforms 78.95% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 33.73%, 1SXP is in line with its industry, outperforming 47.37% of the companies in the same industry.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1SXP is creating value.
The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
The debt/assets ratio for 1SXP is higher compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 1.74, which is an excellent value as it means it would take 1SXP, only 1.74 years of fcf income to pay off all of its debts.
1SXP has a Debt to FCF ratio of 1.74. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
1SXP has a better Debt to Equity ratio (0.09) than 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | N/A |
ROIC/WACC1.73
WACC8.06%
2.3 Liquidity
1SXP has a Current Ratio of 1.57. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.57, 1SXP perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
1SXP has a Quick Ratio of 1.17. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Quick ratio of 1.17 is on the low side compared to the rest of the industry. 1SXP is outperformed by 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -3.00% in the last year.
Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.04% on average per year.
Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 2.86% in the last year.
1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.84% yearly.
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.56% on average per year.
The Revenue is expected to grow by 7.81% on average over the next years.
EPS Next Y4.64%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.56%
Revenue Next Year3.22%
Revenue Next 2Y6.56%
Revenue Next 3Y8.07%
Revenue Next 5Y7.81%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 22.32, 1SXP is valued on the expensive side.
68.42% of the companies in the same industry are more expensive than 1SXP, based on the Price/Earnings ratio.
1SXP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.38.
1SXP is valuated rather expensively with a Price/Forward Earnings ratio of 17.88.
1SXP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 73.68% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.86, 1SXP is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.32 | ||
| Fwd PE | 17.88 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 78.95% of the companies listed in the same industry.
68.42% of the companies in the same industry are cheaper than 1SXP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 65.77 | ||
| EV/EBITDA | 12.38 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
1SXP's earnings are expected to grow with 12.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.81
PEG (5Y)N/A
EPS Next 2Y10.58%
EPS Next 3Y12.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.76%, 1SXP is not a good candidate for dividend investing.
In the last 3 months the price of 1SXP has falen by -20.84%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
1SXP's Dividend Yield is a higher than the industry average which is at 0.71.
With a Dividend Yield of 0.76, 1SXP pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.76% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.41% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.41%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
FRA:1SXP (9/19/2025, 7:00:00 PM)
21.65
+0.05 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.26B
Analysts76.84
Price Target29.89 (38.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.76% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.41%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.42%
PT rev (3m)-1.93%
EPS NQ rev (1m)-3.97%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.29%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)-0.79%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.36%
Revenue NY rev (3m)-1.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.32 | ||
| Fwd PE | 17.88 | ||
| P/S | 3.34 | ||
| P/FCF | 65.77 | ||
| P/OCF | 16.02 | ||
| P/B | 3.78 | ||
| P/tB | 3.91 | ||
| EV/EBITDA | 12.38 |
EPS(TTM)0.97
EY4.48%
EPS(NY)1.21
Fwd EY5.59%
FCF(TTM)0.33
FCFY1.52%
OCF(TTM)1.35
OCFY6.24%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)4.81
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROCE | 17.04% | ||
| ROIC | 13.93% | ||
| ROICexc | 14.46% | ||
| ROICexgc | 14.87% | ||
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% | ||
| FCFM | 5.08% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexcg growth 3Y-8.59%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204.37% | ||
| Cap/Sales | 15.78% | ||
| Interest Coverage | 12.16 | ||
| Cash Conversion | 76.71% | ||
| Profit Quality | 33.75% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.06%
ROIC/WACC1.73
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y4.64%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.56%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year3.22%
Revenue Next 2Y6.56%
Revenue Next 3Y8.07%
Revenue Next 5Y7.81%
EBIT growth 1Y12.19%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year39.55%
EBIT Next 3Y25.42%
EBIT Next 5Y18.43%
FCF growth 1Y-28.77%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.41%
OCF growth 3Y19.45%
OCF growth 5YN/A